SGLT2 inhibitors (SGLT2i) demonstrated a consistent reduction in kidney disease progression, acute kidney injury (AKI), and all-cause hospitalization regardless of whether a patient has type 2 diabetes or the level of baseline albuminuria.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
